23-54) weeks and a median weight of 1.6 (range: 0.4-6.8) kg. The model predicted the observed vancomycin concentrations with reasonable precision. For all vancomycin concentrations, the median prediction error was -0.8 (95% CI: -1.4 to -0.4) mg/L and the median absolute prediction error was 3.0 (95% CI: 2.7-3.5) mg/L. No trends in NPDE across weight, postmenstrual age, serum creatinine, or time after dose were observed. Conclusion: An evaluation of a recently published neonatal vancomycin population pharmacokinetic model in a large external dataset supported the predictive performance and generalizability of the model. This model may be useful in evaluating neonatal vancomycin dosing regimens and estimating the extent of drug exposure.
Results: A total of 243 neonates were studied with a median postmenstrual age of 33 (range:
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INTRODUCTION

METHODS
Validation Cohort
Approval to conduct this study was granted by (used in the current external validation cohort), a previously described linear conversion factor was applied to all of the enzymatic serum creatinine concentrations included in this external validation (enzymatic concentration ¼ 1:050 Â Jaffe method concentration À 0:122) [12] . Exclusion criteria included a diagnosis of congenital kidney disease, major congenital heart disease (other than ventricular septal defect, atrial septal defect, or patent ductus arteriosus), or extracorporeal membrane oxygenation during the vancomycin course.
Model Evaluation
The published neonatal vancomycin population pharmacokinetic model was implemented in the non-linear mixed effects modeling software NONMEM 7.2 (ICON Development Solutions, Ellicott City, MD, USA) as previously described [7] . Briefly, a one For each neonate in the external validation cohort, vancomycin concentrations were then predicted using the parameters of the population pharmacokinetic model and simulating the actual dosing regimen given to the neonate (using the NONMEM MAXEVAL = 0 POSTHOC command). Only concentrations at times for which a neonate had therapeutic drug monitoring performed were simulated.
Model predicted vancomycin concentrations (PRED from the NONMEM output) were then compared with the corresponding observed vancomycin concentrations. As described by Sheiner and Beal [13] , the bias and precision of the model were assessed by calculating the median prediction error and median absolute prediction error for the first trough and peak concentration according to the following formulas:
Prediction error ðbiasÞ:
Absolute prediction error ðprecisionÞ:
where Conc pred refers to the model predicted vancomycin concentration and Conc obs refers to the observed vancomycin concentration. 
RESULTS
External Validation Cohort
Overall, 243 neonates had vancomycin dose and concentration data available and served as the external validation cohort (see Fig. S1 
Model Evaluation
The vancomycin pharmacokinetic model adequately described the observed vancomycin concentrations in the external cohort of [7] b Patient characteristics of the 243 neonates used in the current external validation c The serum creatinine concentration in the model derivation cohort was measured using the Jaffe method. The serum creatinine concentration in the external validation cohort was measured using the enzymatic method and was converted to a Jaffe-standardized equivalent using a linear equation described by Srivastava et al. [12] . Converted values are presented in the table above neonates (Fig. 1a ). Model predicted vancomycin concentrations (PRED) were slightly lower than the observed concentrations (median prediction error -0.8 [95% CI: -1.4 to -0.4] mg/L). The precision of the model was reasonable with a median absolute prediction error of 3.1 (95% CI: 2.7-3.2) mg/L. The predictive performance of the model for peak and trough concentrations is featured in Table 3 . When incorporating patient concentrations to obtain Bayesian estimates of pharmacokinetic parameters for each neonate, the precision of the model predicted vancomycin concentrations (IPRED) improved (Table 4 ). For example, the median IPRED absolute prediction error was 1.7 (95% CI: 
Trough Concentration and AUC 24
Relationship A linear relationship between increased AUC 24 and higher trough concentrations was observed in the external validation cohort (r 2 = 0.60; Fig. 3a ). AUC 24 was highly variable at a given trough concentration (i.e., a two-to threefold range of AUC 24 was achieved at a given trough concentration), and therefore, AUC 24 could not However, a trough concentration of 11 mg/L predicted the achievement of an AUC 24 C400 in 93% of neonates (Fig. 3b ). The median (range) AUC 24 at this trough concentration was 542 (308 to 649) mg 9 hr/L.
DISCUSSION
External validation of a population pharmacokinetic model is described by the United States Food and Drug Administration as ''the most stringent method for testing a developed model'' [16] . Yet, external validation Even after therapeutic drug monitoring and dose adjustment, only 45% of neonates achieved the goal trough concentration of 10-20 mg/L at any point during their course of therapy. This study clearly reveals the Fig. 3 The association between vancomycin trough concentrations and the extent of drug exposure, as measured by the 24-h area under the curve (AUC 24 ). a Higher vancomycin trough concentrations were associated with higher AUC 24 values, although substantial variability was noted. b The probability of achieving a pharmacokinetic/ pharmacodynamic target associated with clinical and microbiological success for invasive methicillin-resistant Staphylococcus aureus infections (an AUC 24 C400) increased with higher vancomycin trough concentrations. All neonates with a trough C12 mg/L had an AUC 24 C400, although many neonates achieved the AUC 24 target with lower trough concentrations significant clinical challenge associated with reliably achieving therapeutic and safe vancomycin concentrations in this highly variable patient population [4] . More innovative vancomycin dosing strategies and approaches are needed in neonates that can help providers personalize empiric dose selection, interpret therapeutic drug monitoring data, and adjust dosing so that exposure targets are achieved.
Population pharmacokinetic models are a powerful tool that can aid clinicians and help inform dosing decisions [18, 19] . By incorporating patient-specific characteristics, dosing information, drug concentrations, and consideration of the variability between patients, population pharmacokinetic models offer the opportunity to provide a more personalized approach to therapeutic decision making. This is especially valuable in a highly variable population, such as neonates, receiving a narrow therapeutic window drug such as vancomycin.
In adults, Bayesian approaches utilizing population pharmacokinetic models have already been shown to have the potential to help support vancomycin dosing decisions [19, 20] . Advancement of similar approaches in neonates is needed. The development and external validation of a neonatal vancomycin population pharmacokinetic model lays the foundation for this future work. For example, our group is currently developing a modelbased approach to individualize the empiric dose in neonates that incorporates the predictors of weight, postmenstrual age, and serum creatinine. Using a simulation framework, the vancomycin dose for a given neonate that is most likely to achieve an AUC 24 C400 while still maintaining a trough concentration \20 mg/L is calculated. A userfriendly, web-based application is currently being developed to facilitate the adoption of this model in our neonatal intensive care units, including integration into the electronic health record. In addition, the ability to estimate AUC 24 and assist providers with dose adjustment within the clinical workflow would be of high value.
Until more robust clinical dosing support tools are developed, clinicians will continue to rely on trough concentration monitoring to help guide vancomycin dosing in neonates. Our findings reinforce the large variability observed in vancomycin trough concentrations among neonates and the inability of a trough concentration alone to reliably predict an individual neonate's AUC 24 . Targeting an AUC 24 /MIC C400 is recommended by the Infectious Disease Society of America when treating invasive MRSA infections and a trough concentration of 15-20 mg/L is suggested in adults to achieve this target [1, 21] . The current study provides further support that in neonates a vancomycin trough concentration of 15-20 mg/L is unnecessary to achieve an AUC 24 /MIC C400 with an MIC B1 mg/L and that lower trough concentrations are likely adequate based on AUC 24 considerations [7] . Accordingly, a trough concentration of approximately 10 mg/L is likely a reasonable first-line target that will provide adequate exposure for invasive MRSA while also appropriately covering for coagulase negative staphylococcal infections. Further dose adjustment and individualization of the therapeutic approach should be guided by the specific pathogen identified, susceptibility testing, clinical status, etc. For example, for MRSA infections with MICs C2 mg/L, an alternative to vancomycin may be necessary since an AUC 24 /MIC C400 will not be achieved in neonates even at trough concentrations of 15-20 mg/L [7] . Lastly, the extent to which the target AUC 24 /MIC C400 is generalizable to neonates is unclear and requires further study. 
CONCLUSIONS
